Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
AssigneeOncology Sciences Corporation
InventorsThomas J. Slaga, Addanki P. Kumar, William Alworth
Life of this patent
Estimating the term…
Abstract
The use of 2-methoxyestradiol, analogues of 2-methoxyestradiol, their method of synthesis and therapeutic use, and the use of combinations of the 2 methoxyestradiol and its analogues, with and without synergistic compounds (namely eugenol), all in the prevention of initial onset cancers, treatment of existing cancers, and the recurrence of previously existing cancers.
Claims35
A method for inhibiting proliferation and survival of pre-cancerous and cancerous cells comprising the steps of:
- selecting a composition containing 2-methoxyestradiol;
- and
- administering said composition to a cellular aggregation in which is identified suspected pre-cancerous or cancer cells.
A method for inhibiting proliferation and survival of pre-cancerous and cancerous cells comprising the steps of:
- selecting a composition consisting substantially of one or more of 2-methoxy estradiol,2-ethoxyestradiol,2-butoxyestradiol, 17-α-ethynylestradiol
- with methoxy group at position 2,17-α-ethynylestradiol with butoxy group at position 2, 17-α-ethynyl-9-α-fluoroestradiol with methoxy group at position 2;
- and 17-α-ethynyl-9-α-fluoroestradiol with butoxy group at position 2.
- administering said composition to a cellular aggregation in which is identified suspected said pre-cancerous or cancerous cells.
A composition for application to cellular aggregation containing pre-cancerous or cancerous cells consisting in active constituents substantially of one or more agents chosen from a groups consisting of 2-methoxyestradiol,2-ethoxyestradiol,2butoxyestradiol, 17-α-ethynylestradiol with methoxy group at position 2, 17-α-ethynylestradiol with butoxy group at position 2, 17-α-ethynyl-9-α-fluoroestradiol with methoxy group at position 2;
- and 17-α-ethynyl-9-α-fluoroestradiol with butoxy group at position 2.
The use of compositions useful in the inhibition of pre-cancerous or cancerous cell proliferation and cell survival selected from a group consisting essentially of:
- the 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 8, specifically excluding any claim to 2-methyloxyestradiol;
- the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 8;
- the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 8;
- the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 9;
- the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 6;
- the 2-ethyl substituted molecule identified as analogue 14 in FIG. 6;
- and
- the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 7.
A method for inhibiting pre-cancerous or cancerous cell proliferation comprising the steps of:
- selecting a composition from the group consisting of the 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 8, specifically excluding any claim to 2-methyloxyestradiol, the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 8, the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 8, the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 9, the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 6, the 2-ethyl substituted molecule identified as analogue 14 in FIG. 6, or the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 7;
- and
- administering said composition to cells in which is identified suspected pre-cancerous or cancer cells.
A composition for application to pre-cancerous or cancerous cells consisting in active constituents substantially of one or more agents chosen from the 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 8, specifically excluding any claim to 2-methyloxyestradiol, the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 8, the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 8, the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 9, the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 6, the 2-ethyl substituted molecule identified as analogue 14 in FIG. 6, or the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 7.
A method for preventing the onset of cancer and for preventing the recurrence of cancer comprising the administration of a therapeutic dose to a human recipient of one or more compositions selected from the group consisting of:
- 2-methoxyestradiol;;
- the 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 8, specifically excluding any claim to 2-methyloxyestradiol;
- the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 8;
- the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 8;
- the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 9;
- the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 6;
- the 2-ethyl substituted molecule identified as analogue 14 in FIG. 6;
- and
- the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 7.
A method of inducing apoptosis in cancerous tissues comprising the steps of:
- administering a therapeutic dosage of a composition containing 2-methoxyestradiol to a cancerous tissues, said administration continuing at least until the initiation of cell apoptosis in said cancerous tissues.
A method for arresting growth of cancer tissues comprising the steps of:
- administering a therapeutic dosage of a composition containing 2-methoxyestradiol to a cancerous tissue, said administration occurring at a time which, at least for some cells in said cancerous tissue, precedes cell division in the G2/M phase.
Dependencies are inferred from the claim text.